Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

DUBAI: Dubai’s Arab Health medical expo could be the medicine to the Pakistani pharmaceutical and surgical industry’s market ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

The Alliance for Pharmacy Compounding (APC), a trade organisation representing the compounding industry, has claimed that Novo Nordisk is "confusing the fact that the semaglutide molecule is ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

2) Novo Nordisk's CagriSema (cagrilintide and semaglutide), a fixed-dose combination ... lowering therapy based on a double-stranded RNA molecule, pending approval, and has a sales prediction ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...